Menu
Danish drugmaker Novo Nordisk (NVO) has approached Global Blood Therapeutics (GBT), a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.
Update(s):
March 9, 2017: Novo Nordisk’s (NVO) new chief executive is looking at making acquisitions to broaden the Danish drugmaker’s product line-up, in a change of tack that reflects a need for fresh sources of growth at the world’s biggest diabetes company.
May 12, 2017: Novo Nordisk’s (NVO) new chief executive is looking at making acquisitions to broaden the Danish drugmaker’s product line-up, in a change of tack that reflects a need for fresh sources of growth at the world’s biggest diabetes company.